Epithalon vs Klotho
A neutral, side-by-side comparison of two anti-aging & longevity peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Epithalon
Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from Epithalamin, a polypeptide extract of the pineal gland. It has been studied since the 1980s by Russian researchers, primarily Vladimir Khavinson, for its ability to activate telomerase and extend telomere length — one of the few compounds with direct evidence of telomere elongation in human cells.
Full profileKlotho
Anti-aging protein discovered in 1997 whose deficiency causes a syndrome resembling accelerated aging across multiple organ systems. Circulating soluble klotho declines ~40% from age 40–80. Research into klotho-derived peptides and recombinant protein explores neuroprotection, cardiac protection, renal anti-fibrosis, and metabolic anti-aging benefits. The KL-VS polymorphism provides a natural human model of elevated klotho activity.
Full profile| Epithalon | Klotho | |
|---|---|---|
| Category | Anti-Aging & Longevity | Anti-Aging & Longevity |
| Also known as | Epitalon, Epithalone, Tetrapeptide Ala-Glu-Asp-Gly | α-Klotho, soluble Klotho, KL-VS, klotho protein, KL1 domain |
| Evidence | Research-stage | Research-stage |
| Dosing range | 5mg–20mg mg, daily for 10–20 day cycles, 1–2x per year | 1mcg/kg–10mcg/kg mcg/kg, every 3–7 days IV or SC (research) |
| Administration | Subcutaneous injection, Intravenous (clinical studies), Intranasal | Intravenous (research), Subcutaneous injection |
| Key side effects | Generally very well-tolerated, Injection site discomfort, Vivid dreams (commonly reported), Improved sleep depth (often reported as benefit) | Hypophosphatemia (klotho inhibits FGF23 signaling → phosphate wasting), Hypocalcemia (secondary to phosphate effects), Altered vitamin D metabolism, Potential for altered mineral homeostasis with chronic administration |
| Cited sources | 2 references | 2 references |
Key differences
- Administration: Epithalon — Subcutaneous injection, Intravenous (clinical studies), Intranasal; Klotho — Intravenous (research), Subcutaneous injection.
- Dosing units differ: Epithalon is dosed in mg, Klotho in mcg/kg — they operate at different scales.
- Frequency: Epithalon is typically daily for 10–20 day cycles, 1–2x per year; Klotho is every 3–7 days IV or SC (research).
How each works
Epithalon
Epithalon activates telomerase (hTERT), the enzyme responsible for maintaining telomere length. In vitro and animal studies show telomere elongation, extended cell lifespan, and reduced DNA oxidation. Russian clinical studies in aging populations report improved melatonin rhythms, immune function, and reduced cancer incidence over multi-year follow-up.
Klotho
α-Klotho functions as both a transmembrane co-receptor for FGF23 (regulating phosphate and vitamin D) and as a shed soluble circulating factor with FGF23-independent longevity effects. Soluble klotho activates longevity-associated pathways: Nrf2/antioxidant defense, FOXO transcription factors, and Wnt/TGF-β inhibition for anti-fibrotic effects. The klotho-deficient mouse ages rapidly and dies young; klotho-overexpressing mice live 20–30% longer.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.